Research programme: antibacterials - Basilea Pharmaceutical
Latest Information Update: 08 Jan 2024
At a glance
- Originator Basilea Pharmaceutica
- Class Antibacterials; Small molecules
- Mechanism of Action Oxidoreductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 08 Jan 2024 Discontinued - Preclinical for Bacterial infections in Switzerland (unspecified route)
- 06 Jun 2022 Preclinical trials in Bacterial infections in Switzerland (unspecified route), before June 2022 (Basilea Pharmaceutica pipeline, June 2022)
- 18 May 2021 Early research in Bacterial infections in Switzerland